You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Decitabine

Showing 1 - 25 of 493
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

Recruiting
  • AML
  • MDS
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital
Nov 30, 2023

MDS Trial in Hangzhou (IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine)

Recruiting
  • Myelodysplastic Syndromes
  • IV Decitabine
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,Zhejiang University School of Medi
Oct 23, 2023

Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)

Not yet recruiting
  • Myeloid Malignancy
  • Acute Myeloid Leukemia
  • Cleveland, Ohio
    University Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Decitabine
  • +3 more
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023

Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

Not yet recruiting
  • Poor Graft Function
  • Decitabine
  • +3 more
  • (no location specified)
Jun 8, 2023

Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

Healthy Trial in San Antonio (Decitabine, Tetrahydrouridine)

Recruiting
  • Healthy
  • San Antonio, Texas
    Worldwide Clinical Trails Early Phase Services
Apr 14, 2023

Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Mesothelioma
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 1, 2023

Recurrent Acute Myeloid Leukemia Trial in Nashville (Venetoclax, Decitabine, Cedazuridine)

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Mar 22, 2023

Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

Not yet recruiting
  • Elderly AML Patients
  • +4 more
  • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
  • Active Comparator: Standard dose of Venetoclax + Azacitidine
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Oct 3, 2023

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Decitabine
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Decitabine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Poor Graft Function Trial (decitabine, umbilical cord blood, Granulocyte-colony stimulating factor)

Not yet recruiting
  • Poor Graft Function
  • decitabine
  • +4 more
  • (no location specified)
Dec 29, 2022

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Aurora, Colorado
  • +2 more
Jan 3, 2023

PFS Trial (Decitabine Injection, tirelizumab)

Not yet recruiting
  • PFS
  • (no location specified)
Nov 24, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • Biopsy
  • +4 more
  • (no location specified)
Jan 4, 2023

Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -

Recruiting
  • Chronic Myeloid Leukemia in Myeloid Blast Crisis
  • +3 more
  • based decitabine and olverembatinib（HQP1351)chemotherapy
  • Guanzhou, China
    Department of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022

Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 31, 2023

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Refractory Aplastic Anemia Trial in Tianjin (Decitabine)

Terminated
  • Refractory Aplastic Anemia
  • Decitabine
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
Aug 25, 2022